Bristol-Myers Squibb BMY
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Community Sentiment on BMY
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on BMY.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
BMY at a glance
Shares of Bristol-Myers Squibb are flat at $62.14. The company is worth $127.02B, number 158 out of 3753 on our list.
The stock's 52-week band runs $43.34 to $67.94, and the latest print sits 8.5% under the top end of it. Holders are ahead 35.9% over twelve months, but down 2.3% across the last three months.
Price is below the 50-day average ($62.17) but above the 200-day ($59.66); RSI is 51, and the last 30 sessions moved at roughly 34% annualized volatility.
For the quarter ended Sep 2026 it reported $13.07B in revenue, up 6.9% from a year earlier, with $2.16B of net profit (a 18.5% margin).
The stock changes hands at 13.8 times trailing earnings, 41% above its five-year average of 9.8. The median for its industry group is 41.8.
18 analysts follow the stock and the average call is "buy". The mean target, $67.25, sits 8.2% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
BeStock Grade
Composite of 4 factors below, ranked against the 3739 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
18 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BeStock Momentum
BMY is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 442.5% (211.9% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $67.25, 8.2% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $70.00, so shares trade 11.2% below that estimate. On earnings multiple, it sits in the 37th percentile of its own five-year valuation range (cheaper than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Bristol-Myers Squibb: the business
Bristol Myers Squibb sells cancer, blood, immunology and heart drugs, including Eliquis and Opdivo, both facing patent expiries.
What tends to move it. The main question is whether newer products can offset the loss of exclusivity on its biggest sellers later this decade.
Where the case gets weaker. Bristol Myers Squibb's outlook turns on whether newer drugs can ramp up fast enough to replace the revenue Eliquis and Opdivo lose once patent protection ends later this decade. If those launches disappoint or face their own competition, the earnings decline from generic entry would show up with little offsetting from the rest of the portfolio.
Written by hand by the BeStock desk and revised when a business changes. how we work. Spot something out of date? Tell us.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +1.3% | Bullish |
| Price vs 50-day average | 0.0% | Bearish |
| Price vs 200-day average | +4.2% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 51.5 | Bullish |
| MACD (12,26,9) | 0.36 | Bullish |
| Bollinger band position | 62% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Key statistics
Quote as of Nov 10, 2026 7:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.
How BMY ranks on BeStock
Ranks are among the 3,739 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 13.8x earnings, BMY looks cheap against the market, and trades 67% below the 41.8x median among Cancer Research names. The two comparisons do not always agree.
BMY stock: common questions
Where is BMY trading right now?
$62.14 is the latest print for BMY, a move of +0.00% against yesterday's close of $62.14. Today's low and high so far: $61.80 and $63.06.
How big is Bristol-Myers Squibb?
Equity value comes to $127.02B at the current price. By that measure it is number 158 of the 3753 names in our coverage.
What multiple of earnings does BMY sell for?
Buyers pay 13.8 times the last twelve months of profit (EPS $3.46). Averaged over five years the multiple has been 9.8, and today's level ranks in the 37th percentile of its own history.
Is BMY near its 52-week high or low?
The year's floor is $43.34 and the ceiling $67.94. Shares are 8.5% away from that ceiling.
Does Bristol-Myers Squibb pay a dividend?
It does. Payouts over the past twelve months work out to a 4.06% yield; the latest ex-dividend date was October 2, 2026.
Is BMY rated a buy by Wall Street?
Of 18 analysts, 44% say buy, 50% hold and 6% sell. Price targets average $67.25, with the most cautious at $40.00 and the most optimistic at $80.00.
What kind of company is Bristol-Myers Squibb?
Bristol Myers Squibb sells cancer, blood, immunology and heart drugs, including Eliquis and Opdivo, both facing patent expiries.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on BMY.
Sign in to join the discussion.